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Background: To date, there are no reports of intraoperative radiotherapy (IORT) use with long-term follow up as a
method of accelerated partial breast irradiation (APBI) in Asian countries. We initiated a prospective phase I/II
clinical trial of IORT in Japan in 2007, and herein, we report the 5-year follow-up results.
Materials and methods: The following inclusion criteria were used for enrollment in the trial: (1) tumor size < 2.5 cm,
(2) desire for breast-conserving surgery, (3) age >50 years, and (4) negative margins after resection. In February 2009,
the eligibility criteria were changed to include only patients with sentinel lymph node-negative disease. In phase I, the
radiotherapy dose was escalated from 19 Gy/fr to 21 Gy/fr, incremented by 1 Gy per step, with 3 patients in each step.
Doses were escalated after all patients in the preceding cohort had completed treatment and exhibited only grade 1
or 2 toxicities at a given dose level. The recommended phase II dose was set at 21 Gy at 90 % isodose. The primary
endpoint was early toxicity. Secondary endpoints were long-term efficacy and late toxicity. In addition, Hypertrophic
scarring was evaluated retrospectively as a cosmetic outcome by a radiation oncologist.
Results: Between December 2007 and March 2010, 32 women with breast cancer were enrolled in the trial. The
median age was 65 years (51–80 years), and the median follow-up time was 6 years. No recurrence or metastasis was
observed in any patient. Grade 2 fibrosis was detected in 3 patients as an acute adverse event and in 2 patients as a
late adverse event. Ten patients developed a hypertrophic scar 1 year after the IORT; the number of patients decreased
to 7 in the 3 years of follow-up.
Conclusion: The first group of female Asian patients tolerated the treatment with IORT in this Phase I/II study and
remained recurrence-free for more than 5 years after treatment. However, 24 % of the patients developed hypertrophic
scarring, an event that is being further examined in our ongoing multi-center Phase II trial of IORT for early breast
cancer.
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The standard treatment for early breast cancer is breast-
conserving therapy (BCT) with whole-breast external ir-
radiation therapy (WBI) [1]. Local recurrences after
BCT with or without WBI arise most often in the same
quadrant as the primary cancer [2], which has led to* Correspondence: mkawamura@med.nagoya-u.ac.jp
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(APBI), many with promising results [3].
Despite the positive results from clinical trials around
the world, the Japanese Breast Cancer Society has stated
in their guidelines regarding the APBI technique that
there is “not enough evidence to perform in clinical
use”. In addition, they state, "to start APBI, we need to
solve the technical problems arises from breast and body
size difference from Western women" [4] because the
same target dose would result in a higher skin, heart,ss article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
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it difficult to increase the fractional dose.
Intraoperative radiotherapy (IORT) is a form of APBI.
The biggest advantage of IORT is its short course of
treatment and the fact that adjuvant radiotherapy is per-
formed during surgery, eliminating the need for multiple
visits to the hospital for adjuvant radiotherapy. IORT
also offers the advantages of excellent delineation of the
tumor bed under visual control and a high rate of spar-
ing of the normal tissue, especially the skin [5, 6].
There are multiple IORT techniques currently re-
ported. One technique uses electron-beam accelerators
that can be employed in the operating room. This tech-
nique was used in the Phase III electron intraoperative
radiation (ELIOT) trial by the European Institute of
Oncology group [6, 7]. With this method, unnecessary
radiation to the heart and lungs can be avoided by pla-
cing a shield between the mammary gland and the pec-
toralis muscle [6]. Another device used for IORT
consists of a miniature electron beam-driven X-ray
source that provides a point source of low-energy X
rays, with a maximum dose of 50 kV. The radiation
source is surrounded by a conical sheath with a sphere
at the tip of various sizes, and can be inserted into the
surgical cavity tumor excision. A multi-center random-
ized trial using this technique termed “TARGIT” began
in March 2000 [5]. The advantage of this technique is
that does not involve extensive dissection around the
breast to separate it from the skin anteriorly and chest
wall posteriorly as is necessary in electron IORT.
Because IORT using electrons can increase a fractional
dose without increasing the heart and lung dose for
small-breasted patients using a shield [8], we initiated
a prospective phase I/II clinical trial of IORT with
electrons via a mobile linear accelerator, similar to
the ELIOT trial, in Japan in 2007 and reported its
safety in a short-term follow up [9]. Here, we report




The protocol for APBI using the IORT method has been
described previously [9]. The study protocol was ap-
proved by the institutional ethics committee and was
registered with the University Hospital Medical Informa-
tion Network (UMIN) clinical trial registry, number
UMIN 000000918. Written informed consent was obtained
from all patients prior to enrollment in the study. The
inclusion criteria were as follows: (1) tumor size < 2.5 cm,
(2) desire for breast-conserving surgery, (3) age >50 years,
(4) negative margins after resection. In February 2009, the
eligibility criteria were changed to include only patients
with sentinel lymph node-negative disease, due to datasupporting node-positive disease as a risk factor for ipsilat-
eral recurrence [1].
For phase I, the radiotherapy dose was escalated from
19 Gy/fr to 21 Gy/fr, incremented by 1 Gy per step. Each
cohort comprised 3 patients. Doses were escalated after
all patients in the preceding cohort had completed treat-
ment. If patients experienced grade 1 or 2 toxicities at a
given dose level, the dose was escalated to the next level.
If a patient experienced grade 3 toxicity, dose escalation
was discontinued. If a patient experienced grade 4 or 5
toxicities, the study was discontinued. The recom-
mended phase II dose was set at 21 Gy at 90 % isodose.
IORT procedure
After wide local excision of the primary breast cancer
and sentinel node biopsy and/or axillary dissection, a
single dose of IORT (19–21 Gy) was delivered via the
Mobetron® (Intraop Medical, USA) to the tumor bed
using 6 to 12 MeV electron beams. The target area for
radiation was at least 2 cm from the margins. Prior to ir-
radiation, an acrylic resin-Cu disc with a diameter of 6–
10 cm with 1-cm intervals was inserted between the
mammary gland and the pectoralis muscle to shield the
heart and lungs from unnecessary dosing. The disc size
was chosen to be larger than the applicator size. Patients
were excluded from the study if their surgical margins
were positive. Adjuvant chemotherapy and endocrine
therapy were administered after the surgery if indicated.
Study assessments
The patients were evaluated every 3 months for the
first year after surgery and every 6 months after that for
5 years by several breast surgeons and radiation oncolo-
gists independently. Acute and late adverse events in-
cluding pain, fibrosis, dermatitis, infection, hematoma,
and heart and lung events were evaluated prospectively
using the National Cancer Institute Common Termin-
ology Criteria for Adverse Events version 3.0. Local re-
currence was defined as recurrence or new disease
within the treated breast, and was evaluated annually
by using mammography and ultrasonography.
Hypertrophic scarring was evaluated retrospectively as
a cosmetic outcome by a radiation oncologist using
charts or photos. Because the tension to the scar is a
critical factor in hypertrophic scarring [10], the rate of
hypertrophic scarring was assessed according to the fol-
lowing variables: tumor location, tumor size, and side of
the breast.
Results
Between December 2007 and March 2010, 38 female
breast cancer patients were recruited for the trial. Four
patients were ineligible for IORT due to positive mar-
gins. One patient could not receive IORT due to
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patient received IORT but was excluded from the evalu-
ation because the pathology indicated a metastatic
tumor from lung cancer.
A total of 32 patients were eligible for the evaluation.
The median age was 65 years (51–80 years), and the me-
dian follow-up time was 6 years (2.5–7 years). Patient
characteristics are described in Table 1. Of 32 patients, 2
patients were lost to follow-up at 2.5 years and 3 years,Table 1 Patients characteristics (n = 32)
Characteristics Number
(rate%)
Age 50-59 9 (28 %)
60-64 6 (19 %)
65-69 8 (25 %)
70+ 9 (28 %)
Side Left 14 (44 %)
Right 18 (56 %)
Tumor site Upper inner quadrant 12 (38 %)
Lower inner quadrant 1 (3 %)
Upper outer quadrant 16 (50 %)
Lower outer quadrant 2 (6 %)
Central portion 1 (3 %)
Pathological size Tis 3 (9 %)
<1 cm 13 (41 %)
1-2 cm 15 (47 %)
>2 cm 1 (3 %)
Positive nodes None 28 (88 %)
1 4 (13 %)
Tumor grades G1, 2 28 (88 %)
G3 4 (13 %)
Hormone receptor ER+ and/or PgR+ 29 (91 %)
ER- and PgR- 3 (9 %)
HER2 status Positive 3 (9 %)
Negative 29 (91 %)
Molecular subtype Luminal A 27 (84 %)




Triple negative 2 (6 %)
ASTRO consensus statement
categories for the application
of APBI
suitable 16 (50 %)
cautionary 12 (38 %)
unsuitable 4 (13 %)
Adjuvant systemic treatment None 5 (16 %)
Endocrine therapy 22 (69 %)
Chemotherapy 3 (9 %)
Endocrine and
Chemotherapy
2 (6 %)respectively. Neither patient had experienced any ad-
verse events or recurrence at their last follow-up. The
other 30 patients completed the protocol-specified
5 years of follow-up. Ipsilateral breast tumor recurrence
(IBRT) to either the tumor bed or elsewhere was not ob-
served in any patients. Similarly, regional lymph node or
distant metastasis was not observed in any patient.
There were no breast cancer-related deaths, but 1 pa-
tient died from unrelated causes after 4 years of follow-
up. Grade 2 (G2) fibrosis was detected in 3 patients as
an acute adverse event and in 2 patients as a late adverse
event. No other adverse event greater than G2 including
hematoma, infection, pain, or dermatitis was observed.
Additionally, no patients experienced any lung or heart
events.
Of 32 patients, we were unable to evaluate cosmesis in
3. In the other 29 patients, hypertrophic scarring was ob-
served in 10 patients 1 year after the IORT; the number of
patients exhibiting hypertrophic scarring decreased to 7
patients in the 3-year follow-up (Fig. 1) without any treat-
ment for hypertrophic scarring. Table 2 outlines the po-
tential predictors of hypertrophic scarring lasting for more
than 3 years, and Fig. 2 depicts hypertrophic scarringFig. 1 A patient with hypertrophic scarring that disappeared by the
3-year follow-up. a) The scar 1 year after IORT. b) Hypertrophic
scarring at the 3-year follow up
Table 2 Predictors of hypertrophic scar lasted for more than
3 years
Rate of hypertrophic scar
Scar location Inner (AB) 2/13(15 %)
Outer (CD) 5/19(26 %)
Sides Right 6/18(33 %)
Left 1/14(7.1 %)
T size <1 cm 4/16(25 %)
≧1 cm 3/16(19 %)
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ber of patients, a valid statistical evaluation was not
possible.Discussion
This study is the first IORT report in Asian women with
long-term follow-up and cosmetic evaluation focused on
hypertrophic scarring. Importantly, our study did not re-
port any grade 3 or greater adverse events as described
by other previous studies [7, 11].
Veronesi et al. reported the 5.8-year follow-up results
of a randomized controlled equivalence trial comparing
IORT with electrons and external radiotherapy (EBRT)
for early breast cancer (ELIOT) in 1305 patients [7].
They concluded that APBI using the IORT technique re-
sulted in a significantly higher IBRT of 4.4 % compared
to 0.4 % in the whole-breast irradiation group. However,
the differences in survival were not reported and the ad-
verse events to the skin were significantly fewer in the
IORT group [7]. In addition, it is very important to note
that the tumor recurrence rate decreases to 1.5 % if pa-
tients are selected based on their suitability for APBI
[12]. Vaidya et al. reported similar results from the
TARGIT-A trial, that the IBRT rate was higher, but thatFig. 2 Hypertrophic scarring or keloid lasting for more than 3 yearsthere were fewer non-breast cancer deaths with TAR-
GIT, attributable to fewer deaths from cardiovascular
causes and other cancers. They also reported that grade
3 or 4 skin adverse events were significantly reduced in
the IORT group (4 of 1720 vs. 13 of 1731, p = 0.029)
[11]. These two large randomized studies concluded
that IORT is a considerable option for selected breast
cancer patients.
Trials such as the Prime II and CALGB9343 trial [13,
14] reported that local relapse rates for cohorts treated
without whole-breast radiation therapy in elderly low-
risk patients were acceptable compared to those using
radiotherapy. In addition, those studies have shown that
these differences in local relapse did not result in a dif-
ference in axillary recurrence, distant metastasis, or
breast cancer-specific survival.
Table 3 summarizes the IBRT rate reported from the
randomized IORT study and omission of radiation ther-
apy for elderly patients. Although it is difficult to com-
pare the results of different studies, the recurrence rates
are very similar in the IORT and omission of radiother-
apy groups even though the omission group has favor-
able prognostic factors. As IORT can be administered
during surgery, avoiding unnecessary irradiation to the
heart, lungs, and skin, a randomized control study com-
paring complete omission of radiotherapy and IORT
should be conducted before evaluating complete omis-
sion of radiotherapy alone because recurrence leading to
mastectomy would lower the patient's quality of life.
In our study, we did not detect tumor recurrence in
any patient. We included 4 patients with one lymph
node metastasis before February 2009. All 4 patients
underwent axillary dissection of level I and II lymph
nodes and additional systemic therapy; 3 patients were
administered adjuvant chemotherapy and 1 patient re-
ceived hormonal therapy. We also included a cautionary
group based on the ASTRO consensus statement [15]
(Table 1). All but one cautionary group patient received
additional adjuvant systemic therapy. We believe this
additional adjuvant therapy played an important role in
our reported lack of tumor recurrence.
The biggest advantage of IORT from the patient’s per-
spective is that adjuvant radiotherapy is performed dur-
ing tumor resection, and therefore, recurring visits for
radiotherapy are unnecessary. Other types of APBI, such
as brachytherapy and three-dimensional conformal
radiotherapy can also shorten the duration of radiother-
apy, but they do not approach the timeframe of IORT.
However, the biggest advantage of IORT from the med-
ical perspective may be different from that of the patient.
Patients who receive IORT with electrons and thoracic
shield will not undergo unnecessary irradiation to the
heart, lungs, and skin. This is very important, especially
in the Asian population whose average breast size is
Table 3 Studies of the IORT and the role of irradiation for elderly
study No. of patients Follow-up (years) Age Treatment Local Recurrence rate P
ELIOT [7] 1305 5.8 48-75 IORT 4.4 % <.0001
WBI 0.4 %
TARGIT-A [11] 1222 5 >45 IORT 3.3 % .042
WBI 1.3 %
PRIME II [13] 1326 5 >65 Tam or AI 4.1 % .0002
Tam or AI + RT 1.3 %
CALGB9343 [14] 636 12.6 >70 Tam 10 % <.001
TamRT 2 %
p, statistical significance; IORT, intraoperative radiotherapy; WBI, whole breast irradiation; Tam, tamoxifen; AI, aromatase inhibitor; RT, radiotherapy; TamRT,
tamoxifen plus radiation therapy
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resulting in increased relative radiotherapy doses being
received by healthy structures such as the heart, lungs,
and skin. As reported in our results, we did not observe
any heart, lungs, or skin toxicities, suggesting that IORT
may be a suitable APBI technique for a small-breasted
population.
The major disadvantage of IORT may be the fact that
7/29 patients experienced hypertrophic scarring that re-
sulted in a poor cosmetic outcome. This finding has
never been reported elsewhere. Hypertrophic scarring is
known to occur more commonly in Asian or other non-
Caucasian populations [16], so this finding maybe very
important to note when applying IORT to these popula-
tions. Although we do not have data regarding the rate
of hypertrophic scarring after mastectomy or BCT with-
out irradiation, in our institution, only 6 % (5/81 pa-
tients) of the breast cancer patients treated in 2010 with
BCT and EBRT experienced hypertrophic scarring. By
comparison, the rate of hypertrophic scarring for pa-
tients treated with IORT was higher. As IORT requires a
wider excision to insert the shield disk, patients without
a risk of hypertrophic scarring should be carefully
chosen. Although we failed to prove statistical signifi-
cance in identifying potential predictors of hypertrophic
scarring, evaluation of the effect of tumor location on
the occurrence of hypertrophic scars is of great interest.
As mentioned previously, tension to the scar is a critical
risk factor for hypertrophic scarring and that hand do-
main and incision type have an intimate involvement in
the tension to the scar. We are now conducting an on-
going multi-center phase II trial of IORT using elec-
trons, which we believe will answer this question.
However, if the risk of hypertrophic scarring is known
prior to the surgery, it may be safer to choose conven-
tional whole-breast radiotherapy, which produces a
smaller scar than IORT, and irradiation to that scar may
suppress the occurrence of hypertrophic scarring [16].
The major limitation of our study was its small num-
ber of patients. This phase I/II study included only 32patients; a larger population is necessary to evaluate if
this method is suitable for Japanese or other Asian pop-
ulations. However, with regard to the potential use of
APBI in the Asian population, it is very important to re-
port its safety, including both early and late toxicities,
and ensure that 21 Gy of electron beams to the tumor
bed is safe for the Japanese population as demonstrated
in the Eliot trial [7].Conclusion
The first group of female Asian patients tolerated the
treatment with IORT in this Phase I/II study and
remained recurrence-free even after more than 5 years
of follow-up. However, hypertrophic scarring was identi-
fied in 24 % of the patients and will be further investi-
gated in our ongoing multi-center Phase II trial of IORT
for early breast cancer.
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